TaiGen Biotechnology Co (太景生技) yesterday announced that it had signed an agreement with China-based Zhejiang Medicine Co (浙江醫藥) that gives the latter exclusive rights to manufacture and commercialize nemonoxacin in China, excluding Hong Kong and Macau.
Nemonoxacin is a novel broad-spectrum non-fluorinated quinolone antibiotic under development for respiratory infections.
Under the terms of the agreement, TaiGen will be responsible for completing the phase 3 clinical trial for community-acquired pneumonia (CAP) in China.
Zhejiang Medicine will be responsible for the manufacturing, sales and marketing of nemonoxacin in China through its wholly owned subsidiary, Xinchang Pharmaceuticals Co (新昌製藥). TaiGen will retain full development and commercialization rights outside the licensed territory including Taiwan, the US, the EU and Japan.
The Taiwanese biotechnology company will receive an upfront payment of US$8 million from Zhejiang Medicine and will receive additional milestones, as well as between 7 and 11 percent of royalties on product sales. The term of the agreement is 20 years.
“Nemonoxacin has demonstrated efficacy and safety in CAP and diabetic foot infection in clinical trials,” TaiGen chairwoman and chief executive officer Hsu Ming-chu (許明珠) told a press conference in Taipei.
“In particular, nemonoxacin has excellent efficacy against drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant MRSA. Nemonoxacin is taken once a day and available in both oral and intravenous formulations,” she said.
TaiGen is completing a phase 3 CAP trial with more than 500 patients from Taiwan and China, and the company expects to file new drug applications in Taiwan and China simultaneously early next year.
According to healthcare information, services and technology provider IMS Health Inc, the global sales of antibiotics amounted to approximately US$11 billion last year and account for almost 20 percent of total pharmaceuticals sales.
The rate of antibiotic-resistant infections in China is among the highest in the world.
According to IMS, global sales of nemonoxacin for CAP and diabetic foot infection could reach US$1.2 billion a year, Hsu said.
She added that TaiGen chose Zhejiang Medicine Co as a partner because it was a first-class pharmaceutical company in China, with a strong antibiotics-marketing team.
“China is the world’s fastest-growing pharmaceutical market. It is poised to overtake Japan as the second-largest pharmaceutical market,” Hsu said. “This partnership will not only set a new record for pharmaceutical licensing involving a Taiwanese and a Chinese company, but hopefully will also become a model for future collaborations.”
“With the conclusion of the partnership in China, we will actively pursue nemonoxacin licensing discussions in other territories, such as the European Union,” Hsu said.
TaiGen currently has Burixafor for stem cell mobilization and TG-2349, a HCV NS3-4A Protease Inhibitor, under phase 2 and phase 1 clinical trials respectively, which will be the company’s focus after nemonoxacin, Hsu added.
Meanwhile, Academia Sinica President Wong Chi-huey (翁啟惠) said yesterday that Taiwan should step up its efforts to expand cooperation with China in clinical research, after the two sides concluded a medical cooperation agreement in December 2010.
Citing Taiwan’s strength in research on diseases that affect only ethnic Chinese, Wong said that clinical trial programs carried out in conjunction with Chinese researchers would further benefit medical research in the field. He made the remark on the second day of a four-day forum to review Taiwan’s policies on the biotech industry.
Additional reporting by CNA
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
ARTIFICIAL INTELLIGENCE: The chipmaker last month raised its capital spending by 28 percent for this year to NT$32 billion from a previous estimate of NT$25 billion Contract chipmaker Powerchip Semiconductor Manufacturing Corp (力積電子) yesterday launched a new 12-inch fab, tapping into advanced chip-on-wafer-on-substrate (CoWoS) packaging technology to support rising demand for artificial intelligence (AI) devices. Powerchip is to offer interposers, one of three parts in CoWoS packaging technology, with shipments scheduled for the second half of this year, Powerchip chairman Frank Huang (黃崇仁) told reporters on the sidelines of a fab inauguration ceremony in the Tongluo Science Park (銅鑼科學園區) in Miaoli County yesterday. “We are working with customers to supply CoWoS-related business, utilizing part of this new fab’s capacity,” Huang said, adding that Powerchip intended to bridge
Qualcomm Inc, the world’s biggest seller of smartphone processors, gave an upbeat forecast for sales and profit in the current period, suggesting demand for handsets is increasing after a two-year slump. Revenue in the three months ended in June will be US$8.8 billion to US$9.6 billion, the company said in a statement Wednesday. Excluding certain items, earnings will be US$2.15 to US$2.35 a share. Analysts had projected sales of US$9.08 billion and earnings of US$2.16 a share. The outlook signals that the smartphone market has begun to bounce back, tracking with Qualcomm’s forecast that demand would gradually recover this year. The San
Clambering hand-over-hand, sweat dripping into his eyes, a durian laborer expertly slices a cumbersome fruit from a tree before tossing it down to land with a soft thump in his colleague’s waiting arms about 15m below. Among Thailand’s most famous and lucrative exports, the pungent “king of fruits” is as distinctive in its smell as its spiky green-brown carapace, and has been farmed in the kingdom for hundreds of years. However, a vicious heat wave engulfing Southeast Asia has resulted in smaller yields and spiraling costs, with growers and sellers increasingly panicked as global warming damages the industry. “This year is a crisis,”